Scholarlink

<p>End-stage heart failure is a deadly disease. Current total artificial hearts (TAHs) carry high mortality and morbidity and offer low quality of life. To overcome current biocompatibility issues, we propose the concept of a soft robotic, hybrid (pumping power comes from soft robotics, innerlining from the patient’s own cells) TAH. The device features a pneumatically driven actuator (septum) between two ventricles and is coated with supramolecular polymeric materials to promote anti-thrombotic and tissue engineering properties. In vitro, the Hybrid Heart pumps 5.7 L/min and mimics the native heart’s adaptive function. Proof-of-concept studies in rats and an acute goat model demonstrate the Hybrid Heart’s potential for clinical use and improved biocompatibility. This paper presents the first proof-of-concept of a soft, biocompatible TAH by providing a platform using soft robotics and tissue engineering to create new horizons in heart failure and transplantation medicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A soft robotic total artificial hybrid heart

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月3日

查看全文
  • Maziar Arfaee,
  • Annemijn Vis,
  • Paul A. A. Bartels,
  • Lucas C. van Laake,
  • Lucrezia Lorenzon,
  • Dina M. Ibrahim,
  • Debora Zrinscak,
  • Anthal I. P. M. Smits,
  • Andreas Henseler,
  • Matteo Cianchetti,
  • Patricia Y. W. Dankers,
  • Carlijn V. C. Bouten,
  • Johannes T. B. Overvelde,
  • Jolanda Kluin

摘要

End-stage heart failure is a deadly disease. Current total artificial hearts (TAHs) carry high mortality and morbidity and offer low quality of life. To overcome current biocompatibility issues, we propose the concept of a soft robotic, hybrid (pumping power comes from soft robotics, innerlining from the patient’s own cells) TAH. The device features a pneumatically driven actuator (septum) between two ventricles and is coated with supramolecular polymeric materials to promote anti-thrombotic and tissue engineering properties. In vitro, the Hybrid Heart pumps 5.7 L/min and mimics the native heart’s adaptive function. Proof-of-concept studies in rats and an acute goat model demonstrate the Hybrid Heart’s potential for clinical use and improved biocompatibility. This paper presents the first proof-of-concept of a soft, biocompatible TAH by providing a platform using soft robotics and tissue engineering to create new horizons in heart failure and transplantation medicine.